ClinicalTrials.gg
RecruitingNCT06430112Updated May 28, 2024

Liposomal Bupivacaine vs Ropivacaine for TAPBs

A Phase 3 interventional study of Liposomal Bupivacaine and Ropivacaine in Abdominal Tumor, Postoperative Analgesia and Liposomal Bupivacaine, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2023, registered May 2024).
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Abdominal Neoplasms with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Abdominal Neoplasms · China.

Started
2023
the only one that year
Phase 3
Only one
of the 10
Registered
5th of 10
by date
Lead sponsor
1 of 10
Sun Yat-sen University

Among the 10 studies in Abdominal Neoplasms with a site in China, this one is the only one that started in 2023, is the only one in phase 3, and was the 5th registered.

Abdominal Neoplasms

42 studies on the registry are indexed under Abdominal Neoplasms; 14 are open to participants now.

Browse Abdominal Neoplasms studies →

Open to participants now

5 of the 10 studies in Abdominal Neoplasms with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 8 Abdominal Neoplasms studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Abdominal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Few studies have compared the efficacy of ultrasound (US)-guided TAP blocks with Liposomal bupivacaine(LB) versus ropivacaine in reducing postoperative opioid usage in patients undergoing laparoscopic lower abdominal tumor Resection. Therefore, we are conducting this prospective, randomized controlled trial to compare the postoperative analgesic effects of LB and ropivacaine for TAP blocks among patients undergoing laparoscopic colorectal procedures.

Read the detailed description

This study aimed to investigate the impact of liposomal bupivacaine (LB) on postoperative opioid usage for ultrasound(US)-guided transversus abdominis plane (TAP) blocks in laparoscopic colorectal resections. We divided 76 patients into two groups. An injection of bilateral TAP blocks was administered to LB group using 133mg liposomal bupivacaine in each block (266mg total), and to R group using 20 ml 0.25% ropivacaine in each block (40 ml total). Opioid consumption and pain scores at 6h, 24h, 48h and 72h were recorded postoperatively, as well as the total intraoperative remifentanil dose, the hospital stay lengths after surgery, and adverse events including dizziness, nausea, and vomiting.

03

Conditions studied

  • Abdominal Tumor
  • Postoperative Analgesia
  • Liposomal Bupivacaine
  • Ropivacaine

Browse trials for

Keywords

  • liposomal bupivacaine
  • ropivacaine
  • transversus abdominis plane block
  • laparoscopic lower abdominal tumor resection
  • opioid consumption
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients undergoing laparoscopic resection of lower abdominal tumors
  2. II-III
  3. Age: 18-70 years.

Exclusion criteria

Exclusion Criteria:

  1. (1) The patient does not agree to participate in the clinical study
  2. (2) The patient has a clear history of opioid tolerance or allergy
  3. (3) The patient has a history of local anesthetic allergy
  4. (4) Previous history of dementia, mental illness or other central nervous system diseases
  5. (5) Have a history of chronic pain or are taking opioids and other analgesics
  6. (6) Patients are generally in poor condition with a history of serious diseases of cardiovascular system, respiratory system, digestive system, urinary system or central nervous system, and may not survive for more than 3 months
  7. (7) The patient had any of the following conditions in the 12 months before surgery: myocardial infarction, severe/unstable angina pectoris, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, pulmonary embolism
  8. (8) Pregnant women
  9. (9) Unable to cooperate with follow-up or poor compliance
  10. (10) Patients with acute myocardial infarction, cardiac arrest or shock during surgery or hospitalization
  11. (11) above grade III.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Liposomal Bupivacaine group

    Liposomal Bupivacaine was used in the group

    Drug: Liposomal Bupivacaine

  • Active comparator
    Ropivacaine group

    Ropivacaine was used in this group

    Drug: Ropivacaine

Interventions

  • After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).

    Also known as: Bupivacaine liposome

  • Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).

    Also known as: Ropivacaine Hydrochloride Injection

06

What researchers measure

Primary outcomes

  1. Postoperative opioid use

    The amount of drug used in the postoperative analgesia pump

    Time frame: 3 days postoperatively

Secondary outcomes

  1. Postoperative pain score

    Postoperative VAS score

    Time frame: 3 days postoperatively

  2. Postoperative adverse reactions

    Postoperative adverse reactions were followed up

    Time frame: 3 days postoperatively

07

Study locations

1 of 1 sites recruiting
  • Jingdun Xie
    Guangzhou, Guangdong 510060, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — https://www.medicalresearch.org.cn/,Time: After completing the academic paper for publication

Supporting information: Study protocol

Time frame: After completing the academic paper for publication

Access criteria: The persons who were willing to study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in May 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
May 28, 2024
StartActual
Nov 1, 2023
Primary completionActual
May 20, 2024
CompletionEst.
Jun 2024
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06430112
Responsible party
Ping Yu (Doctor, Sun Yat-sen University) — Principal investigator
First posted
May 28, 2024
Start date
Nov 1, 2023
Primary completion
May 20, 2024
Completion
Jun 2024 (estimated)
Last update
May 28, 2024

Study contacts

Ping Yu
Contact
yuping@sysucc.org.cn
00-86-13631373286
Jingdun Xie
Contact
xiejd@sysucc.org.cn
00-86-13560380116
Jingdun Xie
principal investigator · Department of Anesthesiology,Sun Yat-Sen University Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion